Please try another search
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Quan Dong Nguyen | - | 2022 | Member of Scientific Advisory Board |
Peter K. Kaiser | - | 2022 | Member of Scientific Advisory Board |
Kuldev Singh | - | - | Member of Scientific Advisory Board |
Anat Loewenstein | - | 2022 | Member of Scientific Advisory Board |
Pablo Villoslada | - | 2022 | Member of Scientific Advisory Board |
Anthony A. Rosenberg | 71 | 2018 | Independent Chairman |
Riad Sherif | 56 | 2017 | CEO & Director |
Martijn Kleijwegt | 69 | 2023 | Independent Director |
Lionel Carnot | 57 | 2017 | Independent Director |
Christophe Baudouin | 63 | 2022 | Member of Scientific Advisory Board |
Arshad M. Khanani | - | 2022 | Chair of Retina Scientific Advisory Board |
Christina M. Ackermann | 59 | 2023 | Independent Director |
Pravin U. Dugel | 60 | 2023 | Independent Director |
Eric D. Donnenfeld | 68 | - | Chair of Cornea Scientific Advisory Board |
David S. Boyer | - | 2024 | Member of Scientific Advisory Board |
Geraldine O'Keeffe | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review